NO944370D0 - Gamma-aminosyre- og L-glutaminsyreanaloger for behandling av anfall - Google Patents

Gamma-aminosyre- og L-glutaminsyreanaloger for behandling av anfall

Info

Publication number: NO944370D0
Authority: NO; Norway
Prior art keywords: treatment; seizures; gamma; amino acid; compound
Prior art date: 1992-05-20

Application number

NO944370A

Other languages

English (en)

Other versions

NO944370L (no

Inventor

Richard B Silverman

Ryszard Andruszkiewicz

Po-Wai Yuen

Denis Martin Sobieray

Lloyd Charles Franklin

Mark Alan Schwindt

Original Assignee

Univ Northwestern

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-20

Filing date

1994-11-16

Publication date

1994-11-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25388336&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO944370(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-11-16 Application filed by Univ Northwestern filed Critical Univ Northwestern

1994-11-16 Publication of NO944370D0 publication Critical patent/NO944370D0/no

1994-11-21 Publication of NO944370L publication Critical patent/NO944370L/no

Links

206010010904 Convulsion Diseases 0.000 title 1
125000003338 L-glutaminyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 title 1
229940024606 amino acid Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
125000004432 carbon atom Chemical group C* 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
206010015037 epilepsy Diseases 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
- C07C247/12—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Enzymes And Modification Thereof (AREA)
Steroid Compounds (AREA)

NO944370A 1992-05-20 1994-11-16 Gamma-aminosyre- og L-glutaminsyreanaloger for behandling av anfall NO944370L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US88608092A	1992-05-20	1992-05-20
PCT/US1993/004680 WO1993023383A1 (en)	1992-05-20	1993-05-18	Gaba and l-glutamic acid analogs for antiseizure treatment

Publications (2)

Publication Number	Publication Date
NO944370D0 true NO944370D0 (no)	1994-11-16
NO944370L NO944370L (no)	1994-11-21

Family

ID=25388336

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO944370A NO944370L (no)	1992-05-20	1994-11-16	Gamma-aminosyre- og L-glutaminsyreanaloger for behandling av anfall

Country Status (22)

Country	Link
EP (1)	EP0641330B1 (no)
JP (2)	JP3856816B2 (no)
KR (1)	KR950701625A (no)
AT (1)	ATE207052T1 (no)
AU (1)	AU677008B2 (no)
CA (1)	CA2134674C (no)
CZ (1)	CZ286106B6 (no)
DE (2)	DE69330949T2 (no)
DK (1)	DK0641330T3 (no)
ES (1)	ES2165857T3 (no)
FI (1)	FI945426A0 (no)
HK (1)	HK1011022A1 (no)
HU (2)	HU222339B1 (no)
LU (1)	LU91112I2 (no)
NL (1)	NL300164I2 (no)
NO (1)	NO944370L (no)
NZ (1)	NZ253459A (no)
PT (1)	PT641330E (no)
RU (2)	RU2140901C1 (no)
SG (1)	SG48288A1 (no)
SK (1)	SK283281B6 (no)
WO (1)	WO1993023383A1 (no)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL113052A0 (en) *	1994-03-23	1995-06-29	Rhone Poulenc Rorer Sa	Recombinant viruses, their preparation and their use in gene therapy
RO120041B1 (ro) *	1994-07-27	2005-08-30	Warner-Lambert Company	Utilizarea gabapentinei, în tratamentul anxietăţii şi panicii
US5792796A (en) *	1994-07-27	1998-08-11	Warner-Lambert Company	Methods for treating anxiety and panic
US5616793A (en) *	1995-06-02	1997-04-01	Warner-Lambert Company	Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) *	1995-06-07	1997-06-10	Warner-Lambert Company	Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US6372792B1 (en) *	1996-04-26	2002-04-16	Guy Chouinard	Method for treating anxiety, anxiety disorders and insomnia
AU714980B2 (en)	1996-07-24	2000-01-13	Warner-Lambert Company Llc	Isobutylgaba and its derivatives for the treatment of pain
CA2263663C (en) *	1996-10-23	2006-05-30	Justin Stephen Bryans	Substituted gamma aminobutyric acids as pharmaceutical agents
WO1999008670A1 (en)	1997-08-20	1999-02-25	Guglietta, Antonio	Gaba analogs to prevent and treat gastrointestinal damage
KR100537707B1 (ko)	1997-09-08	2005-12-20	워너-램버트 캄파니 엘엘씨	항간질 화합물을 포함하는 진통제 조성물 및 이의 사용 방법
AU768277B2 (en) *	1998-05-15	2003-12-04	Warner-Lambert Company Llc	Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
DE69934813T2 (de) *	1998-10-16	2007-10-11	Warner-Lambert Company Llc	Verwendung von gaba analogen zur herstellung eines arzneimittels zur behandlung von manie und bipolaren erkrankungen
AU1602100A (en)	1998-11-25	2000-06-13	Warner-Lambert Company	Improved gamma amino butyric acid analogs
AU779262B2 (en) *	1999-04-08	2005-01-13	Warner-Lambert Company	Method for the treatment of incontinence
US6992109B1 (en) *	1999-04-08	2006-01-31	Segal Catherine A	Method for the treatment of incontinence
US6642398B2 (en)	1999-06-10	2003-11-04	Warner-Lambert Company	Mono-and disubstituted 3-propyl gamma-aminobutyric acids
US7164034B2 (en)	1999-06-10	2007-01-16	Pfizer Inc.	Alpha2delta ligands for fibromyalgia and other disorders
MEP44808A (en) *	1999-06-10	2011-02-10	Warner Lambert Co	Mono- and disubstituted 3-propyl gamma-aminobutyric acids
US6599940B2 (en)	2000-09-13	2003-07-29	Georgetown University	Synthesis of 2-hydroxymethylglutamic acid and congeners thereof
AU2002230398A1 (en)	2000-10-06	2002-04-29	Xenoport, Inc.	Bile-acid conjugates for providing sustained systemic concentrations of drugs
WO2002028881A1 (en)	2000-10-06	2002-04-11	Xenoport, Inc.	Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6462084B1 (en) *	2001-05-14	2002-10-08	Brookhaven Science Associates, Llc	Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
US8048917B2 (en)	2005-04-06	2011-11-01	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
JP2005501013A (ja)	2001-06-11	2005-01-13	ゼノポート，インコーポレイテッド	Ｇａｂａ類似体の全身濃度が持続するアミノ酸コンジュゲート
US7186855B2 (en)	2001-06-11	2007-03-06	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
CA2449673A1 (en)	2001-06-11	2002-12-19	Xenoport, Inc.	Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
US6818787B2 (en)	2001-06-11	2004-11-16	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
EP1485082A4 (en)	2002-02-19	2009-12-30	Xenoport Inc	PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS
US7026351B2 (en)	2002-03-20	2006-04-11	Xenoport, Inc.	Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
US20030225149A1 (en) *	2002-04-30	2003-12-04	Blazecka Peter G.	Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
US7183259B2 (en)	2002-05-17	2007-02-27	Xenoport	Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US7419981B2 (en)	2002-08-15	2008-09-02	Pfizer Inc.	Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7071339B2 (en)	2002-08-29	2006-07-04	Warner Lambert Company Llc	Process for preparing functionalized γ-butyrolactones from mucohalic acid
AU2003297927A1 (en)	2002-12-11	2004-06-30	Xenoport, Inc.	Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
AU2003303041B2 (en)	2002-12-13	2008-07-24	Warner-Lambert Company Llc	Alpha-2-delta ligand to treat lower urinary tract symptoms
KR20050085636A (ko)	2002-12-13	2005-08-29	워너-램버트 캄파니 엘엘씨	섬유근육통 및 기타 질환의 치료를 위한 프레가발린 유도체
CA2451267A1 (en)	2002-12-13	2004-06-13	Warner-Lambert Company Llc	Pharmaceutical uses for alpha2delta ligands
JP2007505149A (ja)	2003-09-11	2007-03-08	ゼノポート，インコーポレイティド	ギャバ類似体のプロドラッグを用いる尿失禁の治療および／あるいは予防
EP2156863A3 (en)	2003-09-12	2011-01-12	Pfizer Limited	Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
CN1871021B (zh)	2003-09-17	2010-07-28	什诺波特有限公司	用gaba类似物的前药治疗或预防多动腿综合征
RU2458049C2 (ru) *	2003-09-17	2012-08-10	Ксенопорт, Инк.	Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк
BRPI0415288B8 (pt)	2003-10-14	2021-05-25	Xenoport Inc	composição farmacêutica compreendendo o ácido 1-{[(a- isobutanoiloxietoxi) carbonil] aminometil}- 1-ciclo- hexano acético cristalino
WO2005060968A1 (en)	2003-12-11	2005-07-07	Sepracor Inc.	Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
MX2007005306A (es)	2004-11-04	2007-06-11	Xenoport Inc	Formas de dosis oral de liberacion sostenida de la prodroga gabapentina.
EP1820502A1 (en)	2006-02-10	2007-08-22	Laboratorios Del Dr. Esteve, S.A.	Active substance combination comprising azolylcarbinol compounds
CA2673545A1 (en)	2006-12-22	2008-07-03	Recordati Ireland Limited	Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids
CA2710152A1 (en) *	2007-12-26	2009-07-02	Generics (Uk) Limited	Processes to pregabalin
TWI380812B (zh)	2008-01-25	2013-01-01	Xenoport Inc	（３ｓ）-胺甲基-５-甲基己酸前藥之晶形及使用方法
US7868043B2 (en)	2008-01-25	2011-01-11	Xenoport, Inc.	Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
WO2009094563A2 (en)	2008-01-25	2009-07-30	Xenoport, Inc.	Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
EP2110372A1 (en)	2008-04-16	2009-10-21	Chemo Ibérica, S.A.	Intermediates for the preparation of Pregabalin and process for their preparation
EP2116539A1 (en)	2008-04-25	2009-11-11	Laboratorios Del. Dr. Esteve, S.A.	1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2123626A1 (en)	2008-05-21	2009-11-25	Laboratorios del Dr. Esteve S.A.	Co-crystals of duloxetine and co-crystal formers for the treatment of pain
CN102216257B (zh)	2008-10-08	2015-11-25	凯飞药业公司	Gaba偶联物及其使用方法
ES2362913B1 (es)	2009-12-24	2012-05-24	Moehs Iberica S.L.	Nuevo método para la preparación de (s)-pregabalina.
EP2353591A1 (en)	2010-02-04	2011-08-10	Laboratorios Del. Dr. Esteve, S.A.	Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en)	2010-02-04	2011-08-10	Laboratorios Del. Dr. Esteve, S.A.	Sigma ligands for use in the prevention and/or treatment of postoperative pain
MX358628B (es)	2010-03-18	2018-08-28	Daiichi Sankyo Co Ltd	Derivado de imidazol sustituido con cicloalquilo.
JP5778133B2 (ja)	2010-03-18	2015-09-16	第一三共株式会社	シクロプロパンカルボン酸誘導体
EP2383255A1 (en)	2010-04-28	2011-11-02	Lacer, S.A.	New compounds, synthesis and use thereof in the treatment of pain
EP2388005A1 (en)	2010-05-21	2011-11-23	Laboratorios Del. Dr. Esteve, S.A.	Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
PL2599487T3 (pl)	2010-07-30	2015-09-30	Toray Industries	Środek terapeutyczny lub środek profilaktyczny przeciwko bólowi neuropatycznemu
EP2415460A1 (de)	2010-08-03	2012-02-08	ratiopharm GmbH	Orale Darreichungsform von Pregabalin
EP2415471A1 (en)	2010-08-03	2012-02-08	Laboratorios Del. Dr. Esteve, S.A.	Use of sigma ligands in opioid-induced hyperalgesia
US8212072B2 (en)	2010-08-13	2012-07-03	Divi's Laboratories, Ltd.	Process for the preparation of pregabalin
EP2524694A1 (en)	2011-05-19	2012-11-21	Laboratorios Del. Dr. Esteve, S.A.	Use of sigma ligands in diabetes type-2 associated pain
EP2527319A1 (en)	2011-05-24	2012-11-28	Laboratorios Del. Dr. Esteve, S.A.	Crystalline forms of pregabalin and co-formers in the treatment of pain
WO2013100873A1 (en)	2011-12-19	2013-07-04	Mahmut Bilgic	Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer)
ES2423254B1 (es)	2012-02-15	2014-03-26	Laboratec, S.L.	Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis
US9066853B2 (en)	2013-01-15	2015-06-30	Warsaw Orthopedic, Inc.	Clonidine compounds in a biodegradable fiber
EP2948139B1 (en)	2013-01-28	2019-06-12	Lopez, Hector, L.	Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor
WO2015091508A1 (en)	2013-12-17	2015-06-25	Laboratorios Del Dr. Esteve, S.A.	SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
AU2014364644A1 (en)	2013-12-17	2016-06-23	Laboratorios Del Dr. Esteve, S.A.	Gabapentinoids and Sigma receptor ligands combinations
WO2016075082A1 (en)	2014-11-10	2016-05-19	Sandoz Ag	Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
CA3099775A1 (en)	2018-05-14	2019-11-21	Xgene Pharmaceutical Inc.	Process for making 1-(acyloxy)-alkyl-carabmate drug conjugates of naproxen and pregabalin
DE202018105573U1 (de)	2018-09-27	2018-10-19	Laboratec	Pharmazeutische Zusammensetzung zur Behandlung der Harninkontinenz und Enuresis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4840460B1 (no) *	1969-02-05	1973-11-30
US4173541A (en) *	1978-06-05	1979-11-06	Cincinnati Milacron Chemicals Inc.	Polynuclear hindered phenols and stabilized organic materials containing the phenols
US4322440A (en) *	1980-06-25	1982-03-30	New York University	Anticonvulsive compositions and method of treating convulsive disorders
US4479005A (en) *	1982-12-16	1984-10-23	The Dow Chemical Company	Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids
US4771038A (en) *	1986-01-21	1988-09-13	Ici Americas Inc.	Hydroxamic acids
US4814342A (en) *	1986-10-31	1989-03-21	Pfizer Inc.	Nor-statine and nor-cyclostatine polypeptides
KR930003864B1 (ko) *	1990-10-19	1993-05-14	한국과학기술연구원	d-2-(6-메톡시-2-나프틸)-프로피온산의 제조방법
AU9137091A (en) *	1990-11-27	1992-06-25	Northwestern University	Gaba and l-glutamic acid analogs for antiseizure treatment
US5198548A (en) *	1992-01-30	1993-03-30	Warner-Lambert Company	Process for the preparation of D(-) and L(+)-3,3-diphenylalanine and D(-) and L(+)-substituted 3,3-diphenylalanines and derivatives thereof

1993
- 1993-05-18 HU HU9403310A patent/HU222339B1/hu active Protection Beyond IP Right Term
- 1993-05-18 SK SK1395-94A patent/SK283281B6/sk not_active IP Right Cessation
- 1993-05-18 RU RU96124481A patent/RU2140901C1/ru active
- 1993-05-18 AT AT93925173T patent/ATE207052T1/de active
- 1993-05-18 JP JP50380794A patent/JP3856816B2/ja not_active Expired - Lifetime
- 1993-05-18 WO PCT/US1993/004680 patent/WO1993023383A1/en active IP Right Grant
- 1993-05-18 DK DK93925173T patent/DK0641330T3/da active
- 1993-05-18 NZ NZ253459A patent/NZ253459A/en not_active IP Right Cessation
- 1993-05-18 AU AU43794/93A patent/AU677008B2/en not_active Ceased
- 1993-05-18 CA CA002134674A patent/CA2134674C/en not_active Expired - Lifetime
- 1993-05-18 EP EP93925173A patent/EP0641330B1/en not_active Expired - Lifetime
- 1993-05-18 HU HU9702482A patent/HU222776B1/hu active IP Right Grant
- 1993-05-18 CZ CZ19942849A patent/CZ286106B6/cs not_active IP Right Cessation
- 1993-05-18 DE DE69330949T patent/DE69330949T2/de not_active Expired - Lifetime
- 1993-05-18 KR KR1019940704158A patent/KR950701625A/ko not_active Application Discontinuation
- 1993-05-18 PT PT93925173T patent/PT641330E/pt unknown
- 1993-05-18 SG SG1996008718A patent/SG48288A1/en unknown
- 1993-05-18 RU RU94046105/04A patent/RU94046105A/ru unknown
- 1993-05-18 ES ES93925173T patent/ES2165857T3/es not_active Expired - Lifetime
- 1993-05-18 DE DE1993630949 patent/DE122004000039I2/de active Active
1994
- 1994-11-16 NO NO944370A patent/NO944370L/no unknown
- 1994-11-18 FI FI945426A patent/FI945426A0/fi not_active Application Discontinuation
1998
- 1998-11-17 HK HK98112078A patent/HK1011022A1/xx not_active IP Right Cessation
2004
- 2004-03-16 JP JP2004075406A patent/JP4297814B2/ja not_active Expired - Lifetime
- 2004-10-06 LU LU91112C patent/LU91112I2/fr unknown
- 2004-11-22 NL NL300164C patent/NL300164I2/nl unknown

Also Published As

Publication number	Publication date
RU2140901C1 (ru)	1999-11-10
HU222776B1 (hu)	2003-10-28
CA2134674C (en)	2004-12-21
FI945426A (fi)	1994-11-18
NZ253459A (en)	1997-03-24
HK1011022A1 (en)	1999-07-02
DK0641330T3 (da)	2001-12-03
NO944370L (no)	1994-11-21
NL300164I2 (nl)	2005-02-01
JP3856816B2 (ja)	2006-12-13
SK283281B6 (sk)	2003-05-02
HU9403310D0 (en)	1995-02-28
ATE207052T1 (de)	2001-11-15
SG48288A1 (en)	1998-04-17
NL300164I1 (nl)	2005-01-03
FI945426A0 (fi)	1994-11-18
WO1993023383A1 (en)	1993-11-25
LU91112I2 (fr)	2004-12-06
JPH07508288A (ja)	1995-09-14
EP0641330A4 (en)	1997-05-28
CZ284994A3 (en)	1995-03-15
ES2165857T3 (es)	2002-04-01
EP0641330A1 (en)	1995-03-08
DE69330949T2 (de)	2002-04-04
SK139594A3 (en)	1995-05-10
JP2004238398A (ja)	2004-08-26
EP0641330B1 (en)	2001-10-17
AU4379493A (en)	1993-12-13
KR950701625A (ko)	1995-04-28
CA2134674A1 (en)	1993-11-25
HU9702482D0 (en)	1998-03-02
PT641330E (pt)	2002-03-28
CZ286106B6 (cs)	2000-01-12
DE122004000039I2 (de)	2006-06-29
HUT71522A (en)	1995-12-28
HU222339B1 (hu)	2003-06-28
AU677008B2 (en)	1997-04-10
DE122004000039I1 (de)	2006-05-18
DE69330949D1 (de)	2001-11-22
JP4297814B2 (ja)	2009-07-15
RU94046105A (ru)	1997-06-20

Publication	Publication Date	Title
NO944370D0 (no)	1994-11-16	Gamma-aminosyre- og L-glutaminsyreanaloger for behandling av anfall
MX9102241A (es)	1994-01-31	Analogos de gaba y de acido l-glutamico para tratamiento contra ataques.
IL110216A (en)	2003-05-29	Valproic acid amide derivatives and pharmaceutical compositions containing them
PT91145A (pt)	1990-02-08	Processo para a sintese de amino-acidos opticamente activos
MX9302970A (es)	1994-05-31	Analogos de acido l-glutamico y gaba para tratamiento anti-ataque.
DE69327092T2 (de)	2000-05-25	Optisch aktives 1-phenylpyrrolidonderivat und dessen herstellung